SCHEMBL10045196

SCHEMBL10045196

c1ccc(C(CCNCCCNCCCCCCCNCCCNCCC(c2ccccc2)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.70
KDM1A O60341 7/20 0.70
MAOB P27338 5/20 0.70
GRIN1 Q05586 2/20 0.68
GRIN2A Q12879 2/20 0.68
SIGMAR1 Q99720 1/20 0.62
HDAC3 O15379 3/20 0.61
HDAC4 P56524 3/20 0.61
HDAC1 Q13547 3/20 0.61
HDAC7 Q8WUI4 3/20 0.61
HDAC2 Q92769 3/20 0.61
HDAC10 Q969S8 3/20 0.61
HDAC11 Q96DB2 3/20 0.61
HDAC8 Q9BY41 3/20 0.61
HDAC6 Q9UBN7 3/20 0.61
HDAC9 Q9UKV0 3/20 0.61
HDAC5 Q9UQL6 3/20 0.61
HTR2A P28223 1/20 0.55
HRH1 P35367 1/20 0.55
MAOA P21397 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10045156 0.98 KCNH2 (0.72) KCNH2KDM1AMAOBGRIN1GRIN2A
SCHEMBL10045174 0.98 KCNH2 (0.72) KCNH2KDM1AMAOBGRIN1GRIN2A
SCHEMBL10045128 0.96 KCNH2 (0.75) KCNH2KDM1AMAOBGRIN1GRIN2A
SCHEMBL11796932 0.89 KCNH2 (0.76) KCNH2KDM1AMAOBGRIN1GRIN2A
SCHEMBL10045154 0.89 KCNH2 (0.62) KCNH2KDM1AMAOBGRIN1GRIN2A
SCHEMBL10045181 0.89 KCNH2 (0.62) KCNH2KDM1AMAOBGRIN1GRIN2A
SCHEMBL10045155 0.89 KCNH2 (0.62) KCNH2KDM1AMAOBGRIN1GRIN2A
Water SCHEMBL11432891 0.87 KCNH2 (0.60) KCNH2KDM1AMAOBGRIN1GRIN2A
Hydrochloric Acid SCHEMBL11126151 0.87 KCNH2 (0.60) KCNH2KDM1AMAOBGRIN1GRIN2A
Hydrochloric Acid SCHEMBL11129733 0.87 KCNH2 (0.60) KCNH2KDM1AMAOBGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148577-B2 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2012-04-03 US disclosed
US-8148577-B2 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2012-04-03 US disclosed
US-20100273745-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2010-10-28 US disclosed
US-20100273745-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2010-10-28 US disclosed
US-20070208082-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS JOHN HOPKINS UNIVERSITY (US) 2007-09-06 US disclosed
US-20070208082-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS JOHN HOPKINS UNIVERSITY (US) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208082-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS KDM1A, JMJD6, SRM KCNH2 1735/4885KDM1A 1/4885MAOB 857/4885
US-20100273745-A1 POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS KDM1A, JMJD6, SRM KCNH2 1735/4885KDM1A 1/4885MAOB 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.